Meridian Life Science Awarded SBIR II By CDC To Develop Rotavirus Vaccine

CINCINNATI--(BUSINESS WIRE)--Meridian Life Science, Inc., (MLS) of Memphis, Tennessee, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce they have been selected by the Centers for Disease Control and Prevention (CDC) to develop a process for manufacture of a rotavirus vaccine. Funding for this activity will be provided through a Small Business Innovation Research (SBIR) contract. Process development will focus on optimization of growth and yield of the virus in cell culture, developing and characterizing a column-based purification process followed by formulation, inactivation and filling of the vaccine. This SBIR II, which follows an initial SBIR I awarded to MLS in 2013, will fund a 15 month research and development effort leading to scale up and manufacture of a rotavirus vaccine for use in clinical trials. MLS is a contract manufacturer offering production of vaccines and challenge stocks which employ current Good Manufacturing Practices (cGMP) as described in 21 CFR Parts 210 and 211.

Help employers find you! Check out all the jobs and post your resume.